Latest / Pharmacy Podcast Network / Psychedelics and Harm Reduction | MindBridge
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:29Speaker 2: Welcome to mind Bridge, the podcast where we connect the
- 0:33Speaker 2: dots between mental health, real life, and the systems meant
- 0:37Speaker 2: to support us. Each episode, we talk to the people
- 0:40Speaker 2: reshaping behavioral health, clinicians, advocates, and disruptors. Because understanding the
- 0:47Speaker 2: mind shouldn't feel like decoding a mystery. Join host doctor
- 0:50Speaker 2: Ryan leban Now on a journey of connection through conversations
- 0:54Speaker 2: right here on mind Bridge.
- 0:56Speaker 3: I am your host, Ryan Paul leban Now, and we
- 0:58Speaker 3: are so excited to have you with us day. And
- 1:00Speaker 3: we have an amazing guest for you, Caleb Graves. Caleb,
- 1:03Speaker 3: how are you doing.
- 1:04Speaker 4: I'm doing great today. Weather's night's finally cooled down a
- 1:07Speaker 4: little bit from how hot this summer's been.
- 1:09Speaker 3: Nice. Nice, Yeah, we've been. We just started the series
- 1:13Speaker 3: mind Bridge. We're pretty excited about it. We actually had
- 1:16Speaker 3: our last episode, which you would have been super interested in.
- 1:19Speaker 3: We had a conversation about artificial intelligence and healthcare. And
- 1:26Speaker 3: I want to kind of start the conversation off kind
- 1:30Speaker 3: of on this note because John Nosta, who I interviewed
- 1:32Speaker 3: actually said something super interesting, and I think that it
- 1:36Speaker 3: ultimately does have to do with psychedelics, in our relationship
- 1:39Speaker 3: with psychedelics, And so as the audience knows we're going
- 1:42Speaker 3: to talk about psychedelics and harm reduction. If you didn't
- 1:44Speaker 3: already see the title, but John Nassa said something. I said,
- 1:49Speaker 3: you know, what is it? What's the issue with artificial
- 1:53Speaker 3: intelligence making us more disconnected than we already are? Right?
- 1:58Speaker 3: If we've got Facebook, and we've got X and we
- 2:02Speaker 3: have Instagram, and we've got all these platforms that really
- 2:05Speaker 3: seemingly disconnect us, isn't artificial intelligence going to make us
- 2:12Speaker 3: more disconnected? And isn't it going to harm our IQ? Right?
- 2:17Speaker 3: Are we going to just simply rely on it so
- 2:19Speaker 3: much that we are no longer thinkers? And I, you know,
- 2:23Speaker 3: posture that I probably use chat GPT too much. But
- 2:28Speaker 3: what he said was really interesting. He said, no, in fact,
- 2:32Speaker 3: we will not be disconnected as artificial intelligence grows. That
- 2:37Speaker 3: actually it will take over and we will be able
- 2:40Speaker 3: to do less of what disconnects us and more of
- 2:44Speaker 3: what connects us. And I thought that was really interesting
- 2:47Speaker 3: because when I think about psychedelics in general, and then
- 2:52Speaker 3: when I think about psychedelics and harm reduction, I still
- 2:55Speaker 3: think of this idea that it's really about connecting with
- 2:59Speaker 3: self health and connecting with others. And I want to
- 3:03Speaker 3: start off by getting your thoughts on that.
- 3:07Speaker 4: Yeah, one of the things that I think is so
- 3:10Speaker 4: fascinating about psychedelics is the language that people use to
- 3:15Speaker 4: describe their benefits or the way that they can change
- 3:17Speaker 4: the way we interact with the world. Elkin Yden published
- 3:22Speaker 4: a great article talking about the different layers of how
- 3:24Speaker 4: psychedelics work, moving from the pharmacological all the way up
- 3:29Speaker 4: to the social, and so a lot of the language
- 3:33Speaker 4: that we hear talks about neuroplasticity, the way the brain
- 3:36Speaker 4: is changing how it connects to itself. But I've been
- 3:41Speaker 4: most interested in research coming out about how psychedelics can
- 3:44Speaker 4: change the way that we interact with each other. So
- 3:48Speaker 4: there's so much trauma and past programming that life puts
- 3:52Speaker 4: on us, bad social experiences, anxieties that we get, those
- 3:56Speaker 4: sorts of things that can create a barrier between ourselves
- 3:59Speaker 4: and other people, contribute to depression, anxiety, that sort of thing,
- 4:03Speaker 4: and psychedelics can reopen those critical moments of social learning
- 4:09Speaker 4: so that we can learn maybe it's safer to be
- 4:11Speaker 4: ourselves with the people that love us, Maybe it's safer
- 4:14Speaker 4: to be ourselves in our work relationships than it used
- 4:18Speaker 4: to be at a different time. So I think psychedelics.
- 4:21Speaker 4: As we see research go on, I'm excited to see
- 4:24Speaker 4: the work that's going to be done on how it
- 4:27Speaker 4: reopens those critical moments of social development for many of
- 4:31Speaker 4: us close when we hit our twenties and our thirties,
- 4:33Speaker 4: so that we can start relearning how to interact with
- 4:36Speaker 4: each other in a healthier way. Again.
- 4:39Speaker 3: Yeah, I think that that's really important to consider because well,
- 4:44Speaker 3: I mean we talk a lot about we're obviously talking
- 4:47Speaker 3: a lot about behavioral health onlind Bridge and on our
- 4:50Speaker 3: exit to the other podcast, our ex Genius, we're talking
- 4:53Speaker 3: about you know, general healthcare, anything goes. But when we
- 4:57Speaker 3: kind of pivot back to what this podcaster is really
- 5:00Speaker 3: about is how are we going to tackle now and
- 5:03Speaker 3: into the future mental health and addiction treatment issues. And
- 5:11Speaker 3: as you know, Caleb, I have had a radical experience
- 5:15Speaker 3: one time with psilocybin that changed my life and it
- 5:21Speaker 3: forever pivoted me in the way in which I viewed
- 5:27Speaker 3: the world, which I viewed myself the way in which
- 5:29Speaker 3: I viewed others, and I'll never be the same for it.
- 5:33Speaker 3: I mean my politics, I mean, honestly, my politics changed,
- 5:37Speaker 3: my relationships changed, The way in which I dealt with
- 5:42Speaker 3: my own mental health changed. It asserted the stability that
- 5:47Speaker 3: I had as somebody in recovery, and so I think
- 5:52Speaker 3: it's really really important that we had more conversations about
- 5:56Speaker 3: how psychedelics are not only can true to recovery, contributing
- 6:03Speaker 3: to general mental health, but really, most importantly for this conversation,
- 6:09Speaker 3: how psychedelics are contributing to harm reduction, right, harm reduction specifically.
- 6:15Speaker 3: I mean, I was actually just on the phone with
- 6:18Speaker 3: one of our clinical partners. We're in four different states.
- 6:22Speaker 3: We've got an ma AT program in North Carolina, Ohio, Oregon,
- 6:28Speaker 3: and Washington, and we were talking about clinical programming and
- 6:32Speaker 3: how we could expand it. And I said, ma'am, wouldn't
- 6:34Speaker 3: it be a beautiful thing if we got to a
- 6:36Speaker 3: space where we could integrate psychedelics in a legal, meaningful
- 6:41Speaker 3: way without having to synthesize them. Talk to me a
- 6:44Speaker 3: little bit about how you view psychedelics within the context
- 6:48Speaker 3: of harm reduction.
- 6:50Speaker 4: Yeah, absolutely, Psychedelics first of all, you can hear a
- 6:57Speaker 4: lot coming from media or from personalities on the internet
- 7:03Speaker 4: about psychedelics as if they're a panacea, something that can
- 7:07Speaker 4: just cure all of our woes and all of our problems.
- 7:10Speaker 4: But I like this framing that psychedels can be part
- 7:13Speaker 4: of a harm reduction program, something that is holistic and integrative,
- 7:18Speaker 4: instead of something that fixes everything. In the nineteen sixties,
- 7:23Speaker 4: there was a experiment from Harvard, the Conquered Prison Experiment,
- 7:27Speaker 4: which tried to see if prisoners who were given psilocybin
- 7:32Speaker 4: would end up being convicted of crimes at a lesser
- 7:34Speaker 4: rate upon re entry into society. And one of the
- 7:38Speaker 4: things that one of these prisoners said has really stuck
- 7:41Speaker 4: out to me and been guiding principle for me, and
- 7:45Speaker 4: that is that he says, there is no drug that
- 7:48Speaker 4: can change you or ey's way of thinking. Only we
- 7:51Speaker 4: can do that. So psychedelics can definitely help, I think,
- 7:55Speaker 4: grease the wheels of our minds to think in new patterns,
- 7:58Speaker 4: imagine new ways of being, and begin down those paths
- 8:03Speaker 4: to being a different person, a healthier person, someone who's
- 8:06Speaker 4: more in touch with ourselves and our planet and with
- 8:09Speaker 4: our society. So I really loved the idea of first
- 8:14Speaker 4: putting psychedelics into an already existing program of care. One
- 8:19Speaker 4: of the critiques of the Conquered Prison experiment was that
- 8:22Speaker 4: so many of the prisoners who underwent this treatment were
- 8:25Speaker 4: also given really intense group and individual therapy talk therapy,
- 8:31Speaker 4: and even in the control groups that were given talk therapy,
- 8:35Speaker 4: they saw increased benefit as well. So I love to
- 8:38Speaker 4: see psychedelics as a catalyst, as something that can enhance
- 8:43Speaker 4: the methods that we already do for harm reduction, instead
- 8:46Speaker 4: of imagining that free of community, free of connection, free
- 8:50Speaker 4: of evidence, back to practices, that we can simply give
- 8:54Speaker 4: somebody psychedelics and it will be a magic bullet for
- 8:56Speaker 4: all their ways.
- 8:58Speaker 3: Yeah, that is one hundred percent the most I think
- 9:02Speaker 3: you've made. The entire point right there of our entire
- 9:06Speaker 3: conversation is that there has to be integration. And I
- 9:09Speaker 3: didn't mention this as the reality is that I took
- 9:11Speaker 3: psilocybin and then I went through an entirely a six
- 9:14Speaker 3: month process afterwards of integrating that experience into my life,
- 9:19Speaker 3: and therefore the change happened. Right. You know, Psychedelics in
- 9:24Speaker 3: and of themselves, although fascinating, it has a shelf life
- 9:32Speaker 3: like any other drug. It really does. And so the
- 9:35Speaker 3: question becomes, if you're not going to take that drug
- 9:37Speaker 3: over and over and over and over and over again,
- 9:40Speaker 3: and you want to have some type of positive outcome,
- 9:43Speaker 3: there has to be some type of integration. And so
- 9:45Speaker 3: therefore talk therapy, CBT, DBT, whatever the case may be,
- 9:51Speaker 3: is pivotal as it relates to how we go about
- 9:55Speaker 3: addressing addressing this. And I think that I think that
- 10:02Speaker 3: clinicians in this space are recognizing more and more that
- 10:10Speaker 3: the work that's being done to pill size psychedelics isn't
- 10:16Speaker 3: going to be the answer, because the grassroots community that
- 10:22Speaker 3: simply wants to see psychedelics decriminalized, for instance, has already
- 10:28Speaker 3: again postured some sensible arguments for that. And now you know,
- 10:34Speaker 3: like for instance, here in Boston and obviously Cambridge, obviously
- 10:40Speaker 3: I'm living in a little bit more of a liberal space,
- 10:43Speaker 3: so the conversation actually happens unlike other places in the world.
- 10:48Speaker 3: But I think that, you know, when I look at
- 10:51Speaker 3: what's haden, what we've seen come out of Cambridge and
- 10:53Speaker 3: the work the science that's come out of it, they're
- 10:57Speaker 3: finally starting to acknowledge that, yes, This is not an
- 11:03Speaker 3: answer in and of itself as we'd hoped. It's why
- 11:07Speaker 3: these companies are actually going bankrupt. It's why these IPOs
- 11:10Speaker 3: are not being successful on Wall Street because they're missing
- 11:15Speaker 3: the point of it all, which was, let's go back
- 11:19Speaker 3: to how this plant medicine was used by indigenous people
- 11:26Speaker 3: and then use it in a manner that is honoring
- 11:31Speaker 3: to that culture, and then as a result, we'll get
- 11:37Speaker 3: the byproduct of that, but we can't get the I
- 11:40Speaker 3: don't believe that we can get the byproduct unless we
- 11:44Speaker 3: in my opinion, and this is just my opinion, because again,
- 11:47Speaker 3: you know a lot of scientists are listening to this,
- 11:49Speaker 3: and I am one too, But I'm telling you, as
- 11:52Speaker 3: a scientist, I do not believe that psychedelics can be
- 11:58Speaker 3: as useful as they could be useful unless you treat
- 12:02Speaker 3: them with a level of sacrament.
- 12:07Speaker 4: Yeah, this is really interesting when it comes to several
- 12:12Speaker 4: of the different substances that have been involved in it's
- 12:17Speaker 4: called them moral panics over the past twenty twenty five years.
- 12:21Speaker 4: I'm particularly thinking of salvia, which is not quite a psychedelic,
- 12:27Speaker 4: but a dissociative hallucinogen, one of the most powerful in
- 12:30Speaker 4: the world that comes out of the central Highlands of
- 12:34Speaker 4: Mexico and suddenly is being dried into these little leaves
- 12:42Speaker 4: and then being smoked by college students whoever who are
- 12:45Speaker 4: buying them, from buying them from gas stations of all places.
- 12:49Speaker 4: In earlier in the two thousands and one of the
- 12:52Speaker 4: things that I found when researching salvia in the way
- 12:56Speaker 4: it was originally used among the Mazateech people was that
- 13:00Speaker 4: it was chewed. It was chewed in small doses over
- 13:04Speaker 4: a period of time to slowly bring up the dose,
- 13:07Speaker 4: and the idea of burning or smoking this substance was
- 13:11Speaker 4: viewed as absolutely absolutely sacrilegious for them and their way
- 13:16Speaker 4: of viewing the world. So the narrative that we got
- 13:19Speaker 4: about salvia in the United States was this is the
- 13:23Speaker 4: most insane, mind blowing unpleasant is another worth drawn around
- 13:29Speaker 4: experience out there. But that's because of the way it
- 13:33Speaker 4: was being used, pulled out of gas stations and smoked,
- 13:37Speaker 4: instead of ever looking at how has this been used
- 13:40Speaker 4: by hundreds of for hundreds of years, by people who
- 13:43Speaker 4: seem to recognize its anti inflammation properties, that seem to
- 13:47Speaker 4: recognize the way that it can just be a relaxant.
- 13:52Speaker 4: These are two radically different ways of viewing the world
- 13:55Speaker 4: and viewing a single substance that then radically changed the
- 13:58Speaker 4: way that we create laws around them. That salvia went
- 14:01Speaker 4: from being some cousin of mint that nobody really cared
- 14:06Speaker 4: about to something that was criminalized around the country. So
- 14:09Speaker 4: the way that we approach these substances, the way we
- 14:11Speaker 4: use these substances, and whether or not we are looking
- 14:15Speaker 4: to extract something from them or work with them, can
- 14:19Speaker 4: determine a lot about the way that we apply these
- 14:23Speaker 4: substances socially and begin to think about them.
- 14:29Speaker 3: So I guess the next question is is are we
- 14:31Speaker 3: doing that? I mean, are we doing that now?
- 14:38Speaker 4: I'm not sure. One of the things one of the
- 14:44Speaker 4: things that I worry about when it comes to when
- 14:49Speaker 4: it comes to psychedelics is this great chasm that's coming
- 14:55Speaker 4: between the incredibly sterile clinical view of research of them
- 15:03Speaker 4: and the sort of data that we get out of
- 15:06Speaker 4: just surveys and interviews with people who use these substances
- 15:11Speaker 4: recreationally or in religious sort of settings. And I see
- 15:16Speaker 4: such a distinct difference between the types of experiences that
- 15:19Speaker 4: are had. I see a great difference in what people
- 15:23Speaker 4: say how much it helps them. And I also worry
- 15:27Speaker 4: that you talked about these psychedelic startups that are looking
- 15:31Speaker 4: for investors look to looking to make money off of
- 15:34Speaker 4: these substances out of psilocybin, mushrooms and mescaline and the like.
- 15:40Speaker 4: And one of the things I must most worry about
- 15:43Speaker 4: with that is that when you're looking for investors, when
- 15:45Speaker 4: you're looking for an injection of capital into into what
- 15:50Speaker 4: you're trying to do, you have a large motivation to
- 15:54Speaker 4: downplay negative things that might come up during psychedelic research
- 16:00Speaker 4: and up play positive things. So instead of finding a
- 16:04Speaker 4: way to work with these substances that is the most
- 16:07Speaker 4: healthy again harm reduction, the most healthy, the most able
- 16:11Speaker 4: to help us, the least likely to harm us. Things
- 16:14Speaker 4: that should be yellow flags for us to adjust perspective,
- 16:18Speaker 4: for us to adjust direction. I'm afraid right now are
- 16:22Speaker 4: being overlooked in favor of how to get the most
- 16:26Speaker 4: money out of it.
- 16:26Speaker 3: At this point, Yeah, it seems to be oxymoronic to
- 16:31Speaker 3: seek capital for this particular thing. There's lots of things
- 16:35Speaker 3: that you can seek capital for that are built by capitalism,
- 16:39Speaker 3: that seem to be sustained by capitalism, that will be
- 16:43Speaker 3: that will both be fed and then ultimately eat itself
- 16:46Speaker 3: in the capitalist system. But it is quite odd to
- 16:52Speaker 3: raise money like like we are a series a round
- 16:57Speaker 3: for ayahuasca. Right, it's just just so culturally it doesn't
- 17:01Speaker 3: make any sense to me. Right. Yeah, I was actually approached.
- 17:04Speaker 3: I won't say the company, but the company has a
- 17:07Speaker 3: stock ticker. I was approached. Locksley Capital was approached about
- 17:12Speaker 3: taking a significant position in the company. And for all
- 17:19Speaker 3: intensive purposes, they look like they were doing incredible work. Right.
- 17:26Speaker 3: The due diligence process really identified that the scientists weren't
- 17:30Speaker 3: just scientists, that there were psychedelic experts that were a
- 17:34Speaker 3: part of this process, and that actually the founders were
- 17:38Speaker 3: recipients and beneficiaries of the psychedelic movement. The problematic issue
- 17:45Speaker 3: is is that it's very difficult to convert psychedelics in
- 17:52Speaker 3: that model into something that is accessible for everyone. And
- 17:57Speaker 3: so for me, I obviously said no. I mean there
- 18:03Speaker 3: was a time when I would invest in companies like Palenteer,
- 18:07Speaker 3: I would invest in companies like McDonald Douglas and Lockheed Martin,
- 18:13Speaker 3: that I would participate in investment rounds for private equity
- 18:18Speaker 3: firms that we're just doing whatever they needed to do
- 18:21Speaker 3: to make a dollar, and that includes the life cycle
- 18:25Speaker 3: of even addiction treatment centers. You know, we see a
- 18:28Speaker 3: lot of those things that are problematic, but you know,
- 18:32Speaker 3: to round that back to psychedelics, we're actually doing harm
- 18:37Speaker 3: by bringing psychedelics into the capitalist system and expecting it
- 18:41Speaker 3: to be able to be supported in the way that
- 18:42Speaker 3: it should be supporting.
- 18:45Speaker 4: Yeah, absolutely, I I see I especially see this when
- 18:53Speaker 4: I've seen folks who are shockingly optimist stick almost naively
- 19:01Speaker 4: so about RFK Junior, Robert F. Kennedy Junior's proclamation about
- 19:08Speaker 4: making psychedelics more accessible through the health Department. Yet some
- 19:13Speaker 4: of these were the same people who were very upset
- 19:17Speaker 4: about his claim that we know the cause of autism
- 19:20Speaker 4: and how to stop it by September of this year.
- 19:23Speaker 4: There seems to be there, seems to be at times
- 19:26Speaker 4: a disjunction when it comes to psychedelics of this is
- 19:30Speaker 4: going to be great, this is going to be wonderful,
- 19:32Speaker 4: and it is, but then not seeing how the system
- 19:37Speaker 4: and the approach that we use to come to these
- 19:39Speaker 4: substances determine the way these substances are then viewed in
- 19:43Speaker 4: the rest of the world. If we're obtaining only a
- 19:45Speaker 4: certain kind of data, and that's the only certain kind
- 19:48Speaker 4: of data we see. It gets into this feedback loop
- 19:51Speaker 4: that I think, unfortunately is going to it's really going
- 19:56Speaker 4: to slow down the progress that we've seen on psychedelic
- 19:59Speaker 4: medicines time in the near future. A lot of people
- 20:02Speaker 4: don't know that in studies on MBMA and psilocybin, those
- 20:07Speaker 4: are the only two that I'm aware of that seven
- 20:09Speaker 4: percent of those who participated in these studies reported that
- 20:12Speaker 4: their depression or anxiety worsened as a result of their
- 20:16Speaker 4: psychedelic experience and probably would have resulted in longer term
- 20:20Speaker 4: care through through talk therapy or whatever else they might need.
- 20:26Speaker 4: This does not mean that these substances shouldn't be used.
- 20:30Speaker 4: But if the narrative that's being blasted out is everyone
- 20:33Speaker 4: who goes through this experience comes out a totally changed
- 20:36Speaker 4: and wonderful person than any level, and you need that
- 20:40Speaker 4: to gain capital to some extent, then anybody who doesn't
- 20:43Speaker 4: fit into that narrative, that again a yellow flag to
- 20:47Speaker 4: say how can we make this better? That will get
- 20:49Speaker 4: overlooked time and time again.
- 20:51Speaker 3: Right, Well, you have one of two options. You're either
- 20:53Speaker 3: number one, it's for everyone, and so we can keep
- 20:56Speaker 3: the price down. Right, It's a simple supply and demand.
- 20:59Speaker 3: We keep the price down because everybody can access it,
- 21:01Speaker 3: and everybody's going to be better off for taking it
- 21:04Speaker 3: micro or macro whatever or like you said, here's the
- 21:10Speaker 3: other The problem is it's only for a few people.
- 21:13Speaker 3: It only really worked for a few people. Here's the
- 21:15Speaker 3: profile of the patient. And then all of a sudden,
- 21:17Speaker 3: the patient population is very small, and now it is
- 21:20Speaker 3: very expensive, and the people that fall into that small
- 21:22Speaker 3: population can't afford it, right, So I mean we and
- 21:27Speaker 3: I was actually quite critical of the way in which
- 21:30Speaker 3: the It's an organization called MAPS, multi Disciplinary Association for
- 21:35Speaker 3: Psychedelic Studies. Rick Doblin. He's been doing that for a
- 21:39Speaker 3: long time. He founded at MAPS in nineteen eighty six.
- 21:43Speaker 3: He really, quite frankly, had done some incredible work for years,
- 21:48Speaker 3: and then all of a sudden, right Pharma got involved, Right,
- 21:50Speaker 3: the money came, you know, just about five six years ago,
- 21:53Speaker 3: the money came, and it really fell apart, right, the
- 21:56Speaker 3: mission fell apart. It was no longer academic, be right,
- 22:01Speaker 3: and so you know there's this fine life. Well, I
- 22:03Speaker 3: mean we see it now, I mean we just see
- 22:05Speaker 3: you know, we were you know, these institutions are losing funding.
- 22:11Speaker 3: The organizations that could fund this research are not going
- 22:14Speaker 3: to because again they can't squeeze enough money out of it.
- 22:18Speaker 3: And I think to your point, I think that that
- 22:21Speaker 3: is just fine, right, I mean, let it burn to
- 22:24Speaker 3: the ground, as far as I'm concerned, right, because there
- 22:27Speaker 3: are there are certain things that we don't need to touch,
- 22:30Speaker 3: we don't need to approve. There's certain things we don't
- 22:32Speaker 3: need to improve upon. What we need to do is
- 22:36Speaker 3: improve access. Right, we're talking about psychedelics when we're talking
- 22:40Speaker 3: about harm reduction together or separately. We need to improve
- 22:45Speaker 3: our ability to be able to access them safely and legally. Right.
- 22:51Speaker 3: And you know, we're again we're having this conversation about
- 22:53Speaker 3: harm reduction right before we got on the podcast, and
- 22:56Speaker 3: I was talking to one of our docs, and we
- 23:01Speaker 3: have to set up another pharmacy in Ohio because we've
- 23:04Speaker 3: got pharmacists that are telling our patients they won't dispense
- 23:10Speaker 3: to them subs, right, subox. We're not talking about high
- 23:15Speaker 3: do its methodone here, guys, but I mean they're they're
- 23:18Speaker 3: in quite frankly in rural red counties. Yeah, I'll just
- 23:24Speaker 3: say it. You know, Fine, I said it, this is
- 23:28Speaker 3: going to be an interest It's going to be an
- 23:30Speaker 3: interesting podcast because I feel I just feel the I
- 23:34Speaker 3: feel it coming on. Right. My producer is probably gonna
- 23:38Speaker 3: cut me off.
- 23:41Speaker 4: But the.
- 23:44Speaker 3: It is hard, It is very very difficult in this
- 23:47Speaker 3: because I think the psychedelics speak to a bigger issue. Right.
- 23:51Speaker 3: For me, psychedelics are about how do I view the world? Right?
- 23:55Speaker 3: What does what is psychedelics? What did psychedelics give me?
- 23:59Speaker 3: That gave me the ability to view the world in
- 24:01Speaker 3: a different way, to ultimately change and in that change
- 24:04Speaker 3: became the person that I am today? Right? Some people
- 24:07Speaker 3: actually probably like the old Ryan better right, to be
- 24:10Speaker 3: quite quite honest. So talk to me a little bit
- 24:14Speaker 3: about how just as an edification for those that don't know, what,
- 24:21Speaker 3: what's the point of it all? Right, Like if you
- 24:24Speaker 3: were to kind of express like Ryan, here's the point,
- 24:27Speaker 3: this is, this is what we're talking about. This is
- 24:28Speaker 3: why psychedelics are so important, not just for harm reduction,
- 24:31Speaker 3: but for the world. What is that?
- 24:35Speaker 4: Yeah, the big I know, it's a big question, that's
- 24:39Speaker 4: a bit, that's a really big question. Yeah. The way
- 24:43Speaker 4: that I see it, the way that I see that
- 24:46Speaker 4: we see psychedelic in its place, is that we are,
- 24:52Speaker 4: like like we said at the beginning of this of
- 24:54Speaker 4: this episode, we are increasingly isolated as people, loneliness, fewer friends,
- 25:01Speaker 4: if youwer connection with family, less connection or feeling of
- 25:04Speaker 4: meaning or value in our in our work, in our careers,
- 25:09Speaker 4: and all this in the background of broader social economic
- 25:13Speaker 4: problems that are beginning to build up, uh and in
- 25:17Speaker 4: the shadow of climate change.
- 25:19Speaker 3: UH.
- 25:19Speaker 4: And so one of the things that I the the
- 25:22Speaker 4: biggest thing that I think psychedelists can do, and psychedelics
- 25:24Speaker 4: isn't the only thing that can do this, but one
- 25:27Speaker 4: of the things that can do is, like I said,
- 25:29Speaker 4: be a catalyst for us to be able to understand
- 25:33Speaker 4: and imagine, because I think we've lost our ability to
- 25:35Speaker 4: imagine new systems, new ways of being, new ways of
- 25:39Speaker 4: connecting with one another. One of the first things that
- 25:43Speaker 4: when I had my first psychedelic trip with psilocybin, one
- 25:49Speaker 4: of the first things that I thought was that when
- 25:52Speaker 4: I came out of the trip was that I simply
- 25:54Speaker 4: needed to be a better person and a better husband,
- 25:58Speaker 4: uh and a better member of my community. And so
- 26:03Speaker 4: that's what I see psychedelics really being most beneficial for
- 26:10Speaker 4: it is just helping us imagine new ways, helping us
- 26:13Speaker 4: imagine new versions of ourselves and our communities that we
- 26:17Speaker 4: can be in, which is exciting but also can be
- 26:22Speaker 4: a little bit frightening because we are talking about change,
- 26:25Speaker 4: and the two things that I think most people are
- 26:28Speaker 4: uncomfortable with is change and the way things are.
- 26:34Speaker 3: Yeah, I think I experienced that every day working in
- 26:36Speaker 3: behavioral health, because I think that every person that we
- 26:39Speaker 3: come in contact with always is faced with this radical
- 26:44Speaker 3: decision right to accept what is or to move forward
- 26:48Speaker 3: with what could be. And we are at a pivotal
- 26:52Speaker 3: point in history right now, and I can't believe that,
- 26:55Speaker 3: honestly that we so I feel beyond grateful that I
- 27:02Speaker 3: get to live in the middle of what we're living through,
- 27:07Speaker 3: not because I like it, but because, like what happened
- 27:13Speaker 3: with the folks that protested against Vietnam, folks that have
- 27:20Speaker 3: stood up for righteousness in other ways, we are presented
- 27:26Speaker 3: with this opportunity to be able to stand up for
- 27:32Speaker 3: what is right. And again, I think that psychedelics represent that.
- 27:40Speaker 3: And I think that when we talk about harm reduction,
- 27:43Speaker 3: we have to say that harm reduction is more than
- 27:47Speaker 3: just reducing the harm of other drugs. Sure, it's about
- 27:52Speaker 3: behavior change in a bigger way, and I think that really,
- 27:59Speaker 3: you know, the Concord Project to a perfect example of that.
- 28:03Speaker 3: Talk to me a little bit about from a policy perspective,
- 28:09Speaker 3: what we're going to need to see in the coming
- 28:12Speaker 3: months years for us to be able to turn a corner,
- 28:16Speaker 3: to be able to not only access psychedelics in the
- 28:20Speaker 3: safest way possible, in the most meaningful way possible, but
- 28:24Speaker 3: also be able to see it integrated into harm reduction
- 28:29Speaker 3: in a way that saves lives.
- 28:31Speaker 4: Sure, and yeah, life saving care is absolutely what psychedelics
- 28:36Speaker 4: are for so many people. The more the more I
- 28:40Speaker 4: was really saddened to see a study when I was
- 28:42Speaker 4: doing a little more research for this show out of
- 28:44Speaker 4: Finland showing not only is the mortality rate overall, excuse me,
- 28:51Speaker 4: the mortality rate from suicide about double for those with
- 28:55Speaker 4: treatment resistant depression, but allegedly so is death by accidents
- 29:00Speaker 4: such as accidental poisoning. That's not that's not how accidents work.
- 29:05Speaker 4: So the level of trauma that we're seeing of mental
- 29:10Speaker 4: illness really harming people today is something that needs to
- 29:16Speaker 4: be addressed immediately. Unfortunately, psychedelics, right now are classified in
- 29:22Speaker 4: the United States as Schedule one substances. So these are
- 29:27Speaker 4: substances that are classified as having no known medical use
- 29:31Speaker 4: and a high potential for addiction and misuse. This is
- 29:37Speaker 4: utterly absern because you look at Schedule two just below that,
- 29:42Speaker 4: and you have fentanyl, and you have cocaine, and you
- 29:48Speaker 4: go another schedule below that, and you have far more
- 29:51Speaker 4: addictive drugs than something of no physical addictive potential like
- 29:55Speaker 4: LSD or shrooms. So when we're looking at policy, when
- 30:00Speaker 4: we're looking at policy, one of the first things that
- 30:02Speaker 4: I would like to see, which I think is an
- 30:04Speaker 4: incremental change, certainly, but is a change that needs to happen,
- 30:08Speaker 4: is moving the classical psychedelics that's your LSD, your psilocybin,
- 30:12Speaker 4: your mescaline, and other novel substances with good potential for treatment,
- 30:18Speaker 4: such as MDMA, perhaps moving that to Schedule three where
- 30:22Speaker 4: there is some known medical use and a low to
- 30:25Speaker 4: moderate risk of addiction or misuse. And I think why
- 30:28Speaker 4: this is important is we have seen this be successful
- 30:31Speaker 4: with ketymine. Ketamine has a potential for addiction. This is known,
- 30:38Speaker 4: this is there, and yet you look across the country
- 30:41Speaker 4: right now, and I mean I just saw several advertisements
- 30:45Speaker 4: for ketamine therapy on a billboard of all places, when
- 30:49Speaker 4: I was traveling a few weeks ago. When you can
- 30:53Speaker 4: get when you can get enough people to have access
- 30:57Speaker 4: to a substance that's schedule three or something similar, then
- 31:01Speaker 4: you can get more data, which you certainly couldn't get
- 31:04Speaker 4: with schedule one, because when you make something schedule one,
- 31:07Speaker 4: it's hard to get more data on it to counteract
- 31:09Speaker 4: the claims that it has no medical use. And then
- 31:12Speaker 4: you can also start looking at creating systems for treatment
- 31:18Speaker 4: that we've seen work with ketamine, so that you can
- 31:21Speaker 4: start to understand in a clinical setting, how do these
- 31:26Speaker 4: substances again those yellow flags, how can we be better
- 31:29Speaker 4: about treating people? When you're looking at then, however, use
- 31:35Speaker 4: outside of the more clinical, sterile setting. Medicine and health
- 31:40Speaker 4: as we know is holistic and does not just rely
- 31:43Speaker 4: on being given a pill or being given a single treatment.
- 31:46Speaker 4: There's a reason that the CDC put in the eviction
- 31:50Speaker 4: moratorium during the COVID nineteen epidemic because of the recognition
- 31:54Speaker 4: that homelessness would have just been mass homelessness would have
- 31:57Speaker 4: been a disaster when it came to the pandemic because
- 32:00Speaker 4: health includes housing. So when we look at what's going
- 32:03Speaker 4: to be necessary for when we look at what's going
- 32:07Speaker 4: to be necessary for getting more people access to these substances,
- 32:10Speaker 4: and you might look like at a model somewhere like
- 32:13Speaker 4: Oregon or Colorado where they've decriminalized or in Colorado legalized psilocybin,
- 32:19Speaker 4: mushrooms and drugs. In general, I think it's important for
- 32:23Speaker 4: us to remember that it's going to take not only
- 32:26Speaker 4: more than legalized clinical treatment, and it's going to take
- 32:30Speaker 4: more than mere decriminalization because these are much much deeper
- 32:35Speaker 4: societal health and behavioral problems. In fact, Oregon just reneged
- 32:40Speaker 4: on their drug decriminalization plan in September because all the
- 32:45Speaker 4: people that used to be in prisons, who used to
- 32:47Speaker 4: be in jails are no longer going to jail, and
- 32:50Speaker 4: so now they're very visible on the street. More people
- 32:54Speaker 4: didn't start using drugs. People simply started to realize how
- 32:58Speaker 4: bad the problem is when you didn't just talk people
- 33:00Speaker 4: in jail. So yes, I think policy change. I'd like
- 33:04Speaker 4: to see a change to Schedule three so we can
- 33:06Speaker 4: get better at research. I'd like to see decriminalization so
- 33:09Speaker 4: that people accessing these non addictive substances don't get put
- 33:14Speaker 4: in jail where we see far worst health outcomes for
- 33:17Speaker 4: something like that. But at the same time, again we
- 33:20Speaker 4: need to recognize these are not psychedelics, are not silver bullets,
- 33:23Speaker 4: they're not panaceas that you need a system and community
- 33:27Speaker 4: of care to ensure that the most good can come
- 33:31Speaker 4: out of using them.
- 33:32Speaker 3: Yeah. I love that you said that, because you know,
- 33:35Speaker 3: when I was thinking about that, I was thinking psychedelics
- 33:40Speaker 3: are way more nuanced than we give it credit for. That.
- 33:47Speaker 3: It's not magic, it's medicine. Yeah, like any medicine. They
- 33:52Speaker 3: can heal or they can harm, depending on how, where
- 33:55Speaker 3: or why they're being used. And we have to be
- 34:00Speaker 3: really cognizant of that. And I think that when we
- 34:03Speaker 3: so let's let's let's transition a little bit to talk
- 34:06Speaker 3: about just psychedelic assistant therapy in general and what the
- 34:12Speaker 3: next step is. So we know that we have to
- 34:14Speaker 3: have a system in place that gives us access. We
- 34:17Speaker 3: know that clinicians and and pharma. Clinicians at the at
- 34:22Speaker 3: the patient level and pharma at the development level are
- 34:28Speaker 3: are looking at things like m d m A, psilocybin
- 34:32Speaker 3: the like. Obviously there are others that are quite beneficial.
- 34:36Speaker 3: I the gain hyahuasca. A lot of great results we're
- 34:42Speaker 3: seeing from both of those as well. Talk to me
- 34:45Speaker 3: a little bit about psychedelic assisted therapy. And for those
- 34:50Speaker 3: that would say, oh, well, this is just you know,
- 34:53Speaker 3: you're just using drugs, right, I mean, this is you know,
- 34:55Speaker 3: you're this is just another problem two fix later on,
- 35:02Speaker 3: talk to us a little bit about why it isn't
- 35:04Speaker 3: about escaping reality that it's really about, in my I
- 35:09Speaker 3: guess for me about confronting it. Mm hmm, yeah, yeah.
- 35:16Speaker 4: I think one one thing to know about here, and
- 35:19Speaker 4: my background is looking at is studying religion and more broadly, uh,
- 35:26Speaker 4: the way that people's belief systems often determine the way
- 35:30Speaker 4: that they see the world if they don't take time
- 35:33Speaker 4: to evaluate those belief systems. One of the big parts
- 35:36Speaker 4: of this conversation then, is just the category of drugs.
- 35:40Speaker 4: What is what is a drug?
- 35:42Speaker 3: What does that mean?
- 35:44Speaker 4: Ketamine is a drug when it's out on the street,
- 35:47Speaker 4: but then when it's taken in a clinical setting, it's
- 35:49Speaker 4: a medical treatment. These are two categories for the same substances.
- 35:53Speaker 4: And I think sometimes folks might unknowingly invest moral meaning
- 36:00Speaker 4: into a substance that is neither moral nor in moral.
- 36:03Speaker 4: It simply is. It simply exists. So one of the
- 36:09Speaker 4: examples of this is in the UN the United Nations
- 36:12Speaker 4: condemnation of drug use. They use the word evil to
- 36:16Speaker 4: describe psychedelics. This is the only place that the UN
- 36:21Speaker 4: uses a moral word like evil in documents of the
- 36:24Speaker 4: same time frames. This is a moral interpretation that people
- 36:28Speaker 4: might not realize they're doing. They think they're being objective,
- 36:32Speaker 4: but they're not. Now when it comes to psychedelics in particularly,
- 36:36Speaker 4: oh aren't you just taking drugs? Isn't this just going
- 36:40Speaker 4: to cause more trouble down the road. Two things that
- 36:44Speaker 4: I'd say to that is, first, like we mentioned before,
- 36:47Speaker 4: psychedelics have an opening up effect. They are not depressants.
- 36:51Speaker 4: They're not the sort of things that you'd see with
- 36:54Speaker 4: opioids or alcohol even that tend to draw people inward
- 37:00Speaker 4: time with excessive use. So you see this reopening to
- 37:06Speaker 4: society and to other people and to yourself in a
- 37:09Speaker 4: way that you would not see using something like heroin,
- 37:12Speaker 4: which again has a much more strong addiction potential as well.
- 37:17Speaker 4: The second thing that I'd say here is to consider
- 37:20Speaker 4: how our society uses and thinks about alcohol. Alcohol causes
- 37:26Speaker 4: the deaths of hundreds of thousands of people in the
- 37:29Speaker 4: United States every year, whether that's a contributive comortality situation
- 37:35Speaker 4: or whether that is drunk driving accidents, drinking too much, whatever,
- 37:40Speaker 4: And yet you never hear a conversation, at least not
- 37:43Speaker 4: for the past hundred years, about whether or not alcohol
- 37:47Speaker 4: should be illegal. Instead, we have created a whole system
- 37:51Speaker 4: of ways to prevent harm around alcohol. I have on
- 37:55Speaker 4: my phone an app that I always use to track
- 37:59Speaker 4: my body weight, many drinks. I've had that sort of
- 38:01Speaker 4: thing to know if I'm okay, can I drive? Do
- 38:04Speaker 4: I need to wait an hour? So I can keep
- 38:06Speaker 4: up with that. We do introductory introductions to alcohol and
- 38:11Speaker 4: most freshmen when they go to college, so they understand
- 38:13Speaker 4: how to be safe. But alcohol's far worse outcomes than
- 38:21Speaker 4: something like psychedelics do psilocybin, lsd DT, far far and more.
- 38:26Speaker 4: The classical psychedelics have no addiction physical addiction potential, and
- 38:31Speaker 4: very very little psychological addiction potential. You cannot overdose easily
- 38:37Speaker 4: on psychedelics. You're talking about doses in some cases thousands
- 38:41Speaker 4: of times more than you could probably eat in a
- 38:43Speaker 4: sitting and when you think about something else, like the
- 38:50Speaker 4: things that people are most scared of from propaganda in
- 38:52Speaker 4: the sixties and seventies, like well, can't psychedelics drive you insane?
- 38:57Speaker 4: It is true that psychedelics can induce psychotic episodes and
- 39:01Speaker 4: people who are already at risk of psychotic episodes, particularly
- 39:04Speaker 4: if they have a close family history of schizophrenic episodes.
- 39:11Speaker 4: But those people can self screen or providers can screen
- 39:15Speaker 4: for that. And so when you look at broader population
- 39:20Speaker 4: studies of groups that take psychedelics regularly, such as the
- 39:24Speaker 4: UDV Church, which is a ayahuasca centered religious group, you
- 39:29Speaker 4: see that. In one particular study, Gosh, I'm forgetting the
- 39:34Speaker 4: year on this and the author come to think of it,
- 39:38Speaker 4: but I think it's from two thousand and seven. It
- 39:40Speaker 4: looked at twenty five thousand members of the UDV Church
- 39:43Speaker 4: who regularly, sometimes weekly, took ayahuasca and over the course
- 39:49Speaker 4: of five years, and it found only about twenty examples
- 39:54Speaker 4: of psychosis that connected to ayahuasca use in five years
- 39:59Speaker 4: of twenty twenty five thousand people. This is an incredibly
- 40:03Speaker 4: small amount, and most of these people, most of these
- 40:06Speaker 4: people ended up being transient events that did not end
- 40:10Speaker 4: in long term illness. Compare this to alcohol, where those
- 40:14Speaker 4: who have alcohol use disorder, which a sizeable sizable minority
- 40:19Speaker 4: of Americans have four percent. One in twenty five people
- 40:24Speaker 4: will have alcohol related psychosis disorders. So if you are
- 40:29Speaker 4: concerned about the outcomes from psychedelics substance use, compare it
- 40:34Speaker 4: to alcohol, and it's a no brainer. We have created
- 40:37Speaker 4: a society where we are okay with alcohol existing. We
- 40:40Speaker 4: create ways for people to be safe. We have adjusted
- 40:43Speaker 4: our healthcare to try to match the negative outcomes. But
- 40:46Speaker 4: for something like psychedelics with known medical treatment value, it
- 40:50Speaker 4: should be a no brainer that these substances should be
- 40:54Speaker 4: socially integrated into the world that we live in and
- 40:57Speaker 4: should be available for medical treatment and personal explorer.
- 41:00Speaker 3: Right. I don't even want to go any further. That
- 41:06Speaker 3: was beautiful. That's exactly. Yeah, that really was I guess
- 41:12Speaker 3: what I would say is and it's what we'll we'll
- 41:15Speaker 3: wrap up with that. I think that was really that
- 41:17Speaker 3: was really important what you just said. I think that
- 41:20Speaker 3: we have to remember that when people hear the word
- 41:23Speaker 3: psychedelic in their minds, it tends to drift to the
- 41:28Speaker 3: sensational mm hmm. And I'm want to I'd like tied
- 41:35Speaker 3: T shirts and music festivals and maybe even the fear
- 41:39Speaker 3: driven rhetoric of you know, a bygone era of this
- 41:42Speaker 3: is your brain on drugs type of talk. Sure, but
- 41:46Speaker 3: we know that, like I said before, that it's far
- 41:48Speaker 3: more nuanced, and that psychedelics aren't magic. There medicine, and
- 41:52Speaker 3: like any other medicine, they can heal, they can harm
- 41:57Speaker 3: depending on how, where and why they're used. And psychedelic
- 42:00Speaker 3: and psychedelic assistant therapy isn't about escaping reality. It's about
- 42:03Speaker 3: confronting it gently, courageously, with guidance under clinical supervision if necessary,
- 42:10Speaker 3: with guidance from a sitter, right from a psychedelic expert,
- 42:16Speaker 3: those that know and care to create a safe space
- 42:20Speaker 3: for consumption. All of these things are so possible now.
- 42:24Speaker 3: I think that it's also important that we acknowledge that
- 42:29Speaker 3: these substances don't cure. They don't cure you. Right. Do
- 42:35Speaker 3: I believe that psilocybin rewires the brain. I do. There's
- 42:38Speaker 3: still still yet to be completely proven, although there's some
- 42:45Speaker 3: baseline studies out there. I'm just a lover of psilocybin
- 42:50Speaker 3: because of my experience with it, and I try to
- 42:54Speaker 3: keep it as spiritual as possible, because for as much
- 42:58Speaker 3: as I want to communicate the science, I think people
- 43:04Speaker 3: just have to get into it for themselves, because I
- 43:08Speaker 3: think a lot of times what will happen is somebody
- 43:10Speaker 3: will hear a podcast like that and they'll say, well,
- 43:12Speaker 3: they're just psychonics, you know, they're just psychonauts. These people
- 43:14Speaker 3: just take psychedelics and they want everybody else to take psychedelics,
- 43:17Speaker 3: and they think it's the best things in sliced bread.
- 43:20Speaker 3: And why wouldn't you because you take psychedelics. Right. But
- 43:24Speaker 3: here's the thing. We don't get to just throw these
- 43:27Speaker 3: tools out into the world and expect that everything's going
- 43:31Speaker 3: to be fine. And when it comes to harm reduction,
- 43:34Speaker 3: harm reduction is not permission right to just haphathitively use
- 43:41Speaker 3: whatever in the hopes that it reduces harm. Right, There
- 43:46Speaker 3: is a strategy here, and it's about protection. It's about safety,
- 43:50Speaker 3: and that's really what we're struggling with right now. It's
- 43:54Speaker 3: about protection. Am I safe as a human being in
- 43:57Speaker 3: the world of which I exist right now? Whether without
- 44:01Speaker 3: a without a substance use disorder, whether without a primary
- 44:04Speaker 3: mental health disorder? Am I protected? Am I safe? And
- 44:08Speaker 3: the reality is that for many of us, many of
- 44:12Speaker 3: our brothers and sisters are not They're simply not. So
- 44:20Speaker 3: when I speak to these things, I speak to the
- 44:22Speaker 3: reality that it's not about cleaning test kits. It's it's
- 44:31Speaker 3: like what you're doing. It's about honest education instead of
- 44:34Speaker 3: scare tactics. It's acknowledgment that people will experiment, so let's
- 44:39Speaker 3: make sure that they don't die trying, right, you know,
- 44:43Speaker 3: I mean, that's the reality people are going to use.
- 44:47Speaker 3: And it's our responsibility as practitioners, as clinicians, as healthcare leaders,
- 44:51Speaker 3: as religious leaders, as spiritual leaders to be there to
- 44:56Speaker 3: protect and to make sure that harm is not cause.
- 45:00Speaker 3: And that is that that is ultimately the point of
- 45:02Speaker 3: what we're talking about today. So it really excites me.
- 45:07Speaker 3: It encourages me to hear you talk about this, Caleb.
- 45:10Speaker 3: You know, you know, I have a deep, deep respect
- 45:13Speaker 3: for you and your work and the work that you're
- 45:15Speaker 3: continuing to do and all of the facets that you
- 45:20Speaker 3: lay your hands on. I think that what I'd like
- 45:25Speaker 3: to do is is certainly give you the last word
- 45:28Speaker 3: and within this spirit that folks, we have a collective
- 45:37Speaker 3: responsibility to make sure that that doorway which I believe
- 45:42Speaker 3: is sacred and quite frankly ancient, that it stays open,
- 45:50Speaker 3: that stays safe, and it stays grounded in care.
- 45:53Speaker 4: Yeah. I went to Bonneru Music festival last month, which
- 45:58Speaker 4: unfortunately got rained out in canceled after the first day,
- 46:03Speaker 4: and one of the things that I did there was
- 46:05Speaker 4: bring harm Reduction KITS, fentanyl test KITS, xileozine test KITS.
- 46:10Speaker 4: Dance Safe has different papers that can handouts that can
- 46:15Speaker 4: tell people about different psychedelics. And when Bonneru got canceled,
- 46:20Speaker 4: I heard couldn't have been older than twenty years old.
- 46:23Speaker 4: This kid say, well, if it's canceled, I might as
- 46:27Speaker 4: well use all my drugs at once. And that was
- 46:30Speaker 4: an instant pop in of let's not do that, let's intervene,
- 46:34Speaker 4: let's chat, let's have what's your name, where you're from?
- 46:37Speaker 4: Why are you doing this? Have you ever done this before?
- 46:41Speaker 4: The community care element and the way it takes to
- 46:44Speaker 4: keep people safe, whether they're in a clinical setting or
- 46:47Speaker 4: out of a clinical setting, is often lost because we
- 46:50Speaker 4: are not building those relationships right now. So again, there's
- 46:55Speaker 4: no drug that can change you, and I as way
- 46:57Speaker 4: of thinking, only we can do that, and the same way.
- 47:01Speaker 4: There is no top to bottom policy that can change
- 47:05Speaker 4: the way that we approach these substances. Only relationships between
- 47:09Speaker 4: you and I and us can do that.
- 47:11Speaker 3: Yeah. I love that we are served by a wonderful
- 47:16Speaker 3: universe and there are grand things that that universe has
- 47:21Speaker 3: for us, and I'm still thankful to share this time
- 47:23Speaker 3: with you and for audience. Thanks for listening. You are
- 47:26Speaker 3: listening to mind Bridge, a behavioral health podcast. Have a
- 47:29Speaker 3: great day.